Baeza, Inmaculada http://orcid.org/0000-0003-2611-5781
de la Serna, Elena
Mezquida, Gisela
Cuesta, Manuel J.
Vieta, Eduard
Amoretti, Silvia
Lobo, Antonio
González-Pinto, Ana
Díaz-Caneja, Covadonga M.
Corripio, Iluminada
Valli, Isabel
Puig, Olga
Mané, Anna
Bioque, Miquel
Ayora, Miriam
Bernardo, Miquel
Castro-Fornieles, Josefina
García-Rizo, Clemente
González-Díaz, Jairo
de Matteis, Mario
de Diego, Héctor
Grasa, Eva
Roldán, Alejandra
Zorrilla, Iñaki
García-Corres, Edurne
Ruíz-Lázaro, Pedro M
de-la-Cámara, Concepción
Rivero, Olga
Escarti, María José
Casanovas, Francesc
Toll, Alba
Verdolini, Norma
Sagué-Vilabella, Maria
Sugranyes, Gisela
Ilzarbe, Daniel
Contreras, Fernando
González-Blanco, Leticia
García-Portilla, María Paz
Gutierrez, Miguel
Zabala, Arantzazu
Rodríguez-Jiménez, Roberto
Sánchez-Pastor, Luis
Usall, Judith
Butjosa, Anna
Pomarol, Edith
Sarró, Salvador
Ibáñez, Angela
Sánchez-Torres, Ana Maria
Balanzá-Martínez, Vicent
,
Funding for this research was provided by:
Instituto de Salud Carlos III (PI08/0208, PI18/0242, INT19-00021)
Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya (2017SGR1355)
Universitat de Barcelona
Article History
Received: 18 March 2022
Accepted: 10 March 2023
First Online: 7 April 2023
Declarations
:
: IB has received honoraria and travel support from Angelini, Otsuka-Lundbeck and Janssen, grants from Spanish Ministry of Health, Instituto de Salud Carlos III. EV has received grants and served as consultant, advisor or CME speaker for the following entities (unrelated to the present work): AB-Biotics, Abbvie, Aimentia, Angelini, Biogen, Celon, Dainippon Sumitomo Pharma, Ferrer, Gedeon Richter, GH Research, Glaxo Smith-Kline, Janssen, Lundbeck, Organon, Otsuka, Sage, Sanofi-Aventis, Sunovion, and Takeda. AG–P has received grants and served as consultant, advisor or CME speaker for the following entities: Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Sanofi-Aventis, Alter, Angelini, Exeltis, Takeda, the Spanish Ministry of Science and Innovation (CIBERSAM),the Ministry of Science (Carlos III Institute), the Basque Government, and the European Framework Program of Research. CD-C holds grants from Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (PI17/00481, PI20/00721, JR19/00024) and has received fees from Exeltis and Angelini. AM has served as a speaker and received honoraria for travel expenses /attending conferences from Otsuka and Angelini. M. Bioque has been a consultant for, received grant/research support and honoraria from, and been on the speakers/advisory board of has received honoraria from talks and/or consultancy of Adamed, Angelini, Casen-Recordati, Ferrer, Janssen-Cilag, Lundbeck, Neuraxpharm, Otsuka, Pfizer and Sanofi, and grants from Spanish Ministry of Health, Instituto de Salud Carlos III (PI20/01066). MA has held a Río Hortega grant from Instituto de Salud Carlos III (Spanish Ministry of Science and Innovation). M. Bernardo has been a consultant for, received grant/ research support and honoraria from, and been on the speakers/advisory board of ABBiotics, Adamed, Angelini, Casen Recordati, Janssen-Cilag, Menarini, Rovi and Takeda. CG-R has received honoraria/travel support from Adamed, Angelini, Janssen-Cilag and Lundbeck. JG-D has been an advisor/speaker for, or received travel support from Janssen, Eurofarma, Servier, Sanofi, Lilly, and Pfizer. CD-L-C received financial support to attend scientific meetings from Janssen-Cilag, Almirall, Eli Lilly, Lundbeck, Rovi, Esteve, Novartis, and Astrazeneca. NV has received financial support for CME activities and travel funds from the following entities (unrelated to the present work): Angelini, Janssen-Cilag, Lundbeck, Otsuka. MS-V has received financial support for CME activities or travel funds from Janssen-Cilag and Lundbeck, and has served as a speaker for Casen Recordati. GS has received speaker fees by Angelini Pharma. RR-J has been a consultant for, spoken in activities of, or received grants from: Instituto de Salud Carlos III, Fondo de Investigación Sanitaria (FIS), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid Regional Government (S2010/ BMD-2422 AGES; S2017/BMD-3740), JanssenCilag, Lundbeck, Otsuka, Pfizer, Ferrer, Juste, Takeda, Exeltis, Casen-Recordati, Angelini. AI has received research support from or served as speaker or advisor for Janssen-Cilag, Lundbeck and Otsuka. The remaining authors have no personal affiliations or financial relationships with any commercial interests to disclose in connection with the article.